Company intelligence / Profile preview

Aquanova AG

Darmstadt, Hessen, Germany

Ownership: Private
Development stage: Other

Overview

Aquanova AG has developed and commercialized the NovaSOL® micellar encapsulation platform, which demonstrably improves bioavailability of hydrophobic natural compounds like curcumin and resveratrol, enabling their use in clinical and consumer applications; clinical results for healthspan and CNS indications derive from partner programs such as Jupiter Neurosciences' JOTROL™ (resveratrol), currently in Phase II for Parkinson’s Disease.

Therapeutic areas: NeurologyOther
Modalities: Small molecule (micellar encapsulated)Biologic (for certain actives)
Industry: Chemicals & Materials

Partnerships

Jupiter Neurosciences (JOTROL™ resveratrol for CNS, ageing, Phase II trial)

Beyond the preview

Go deeper on Aquanova AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquanova AG.

Explore the full profile